Biologic therapy more costly than triple therapy for RA
Biologic therapy is more costly than triple therapy for first-line treatment of active rheumatoid arthritis (RA) and unlikely to be cost effective, according to findings of an analysis of published in Annals of Internal Medicine.1 A decision analytic model based on data in 324 participants in the Rheumatoid Arthritis Comparison....
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 780, Seite 12 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Cost analysis |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1996367358 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1996367358 | ||
| 003 | DE-627 | ||
| 005 | 20230511181117.0 | ||
| 007 | tu | ||
| 008 | 170901s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171125 |
| 035 | |a (DE-627)OLC1996367358 | ||
| 035 | |a (DE-599)GBVOLC1996367358 | ||
| 035 | |a (PRQ)proquest_journals_19265293330 | ||
| 035 | |a (KEY)0248955420170000000078000012biologictherapymorecostlythantripletherapyforra | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a Biologic therapy more costly than triple therapy for RA |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Biologic therapy is more costly than triple therapy for first-line treatment of active rheumatoid arthritis (RA) and unlikely to be cost effective, according to findings of an analysis of published in Annals of Internal Medicine.1 A decision analytic model based on data in 324 participants in the Rheumatoid Arthritis Comparison... | ||
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Internal medicine | |
| 650 | 4 | |a Health care access | |
| 650 | 4 | |a Cost analysis | |
| 650 | 4 | |a Medicine | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 780, Seite 12 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:780 |g pages:12 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1926529333 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 780 |h 12 | ||